10 recruiting, 8 active not recruiting, 3 completed, 1 enrolling by invitation. 25 Phase 3, 4 Phase 2.
Follow abiraterone: new trials by email Literature Review of abiraterone trials Research Report on abiraterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) Saruparib, Placebo, Enzalutamide - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Recruiting | AstraZeneca | 1330 | 2026-09-15 | 2026-10-15 |
| A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302] Risvutatug rezetecan (Ris-Rez), Enzalutamide, Abiraterone - Neoplasms, Prostate | Phase 3 | Recruiting | GlaxoSmithKline | 684 | 2026-09-01 | 2026-10-02 |
| A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 180 | 2026-09-01 | 2026-07-23 |
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC | Phase 3 | Recruiting | University College, London | 1500 | 2026-08-28 | 2026-10-16 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone - Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 700 | 2025-08-06 | 2026-10-14 |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC AAA817, ARPI, Standard of Care - Prostate Cancer | Phase 3 | Recruiting | Novartis Pharmaceuticals | 940 | 2025-07-01 | 2026-10-15 |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer (Adenocarcinoma) | Phase 3 | Recruiting | Canadian Cancer Trials Group | 830 | 2025-05-28 | 2026-07-14 |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer BMS-986365, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | Celgene | 960 | 2025-03-13 | 2026-09-30 |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) Xaluritamig, Abiraterone, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | Amgen | 707 | 2024-12-09 | 2026-05-15 |
| The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) 177Lu-TLX591, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 520 | 2024-07-26 | 2026-07-21 |
| A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Abemaciclib, Abiraterone, Prednisone or Prednisolone - Prostatic Neoplasms, Neoplasm Metastasis | Phase 3 | Active not recruiting | Eli Lilly and Company | 925 | 2022-04-14 | 2026-07-01 |
| 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer 177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide - Metastasis From Malignant Tumor of Prostate | Phase 3 | Active not recruiting | Curium US LLC | 439 | 2022-02-14 | 2026-09-04 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis | Phase 2 / Phase 3 | Active not recruiting | VA Office of Research and Development | 378 | 2021-07-01 | 2026-10-19 |
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent VERU-111, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | Phase 3 | Terminated | Veru Inc. | 105 | 2021-06-24 | 2024-02-05 |
| Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment [Lu-177]-PNT2002, Abiraterone, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Active not recruiting | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 455 | 2021-02-25 | 2026-01-13 |
| Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Cabozantinib, Atezolizumab, Abiraterone Acetate - Metastatic Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Active not recruiting | Exelixis | 575 | 2020-10-19 | 2025-12-18 |
| ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin - Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Recruiting | Karolinska Institutet | 750 | 2019-02-01 | 2025-04-09 |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Abiraterone, Bicalutamide, Degarelix - Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 1273 | 2018-09-24 | 2026-10-08 |
Showing 20 of 25. Sign in to see all of them.
Prostatic Neoplasms (21) · Neoplasm Metastasis (4) · Neoplasms (2) · Adenocarcinoma (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Prostatic Neoplasms, Castration-Resistant (1) · Urogenital Neoplasms (1)
AstraZeneca (3) · Exelixis (2) · Alliance for Clinical Trials in Oncology (1) · Amgen (1) · Bayer (1) · Canadian Cancer Trials Group (1) · Celgene (1) · Curium US LLC (1) · Eli Lilly and Company (1) · GlaxoSmithKline (1) · Hoffmann-La Roche (1) · Karolinska Institutet (1) · Medical Research Council (1) · Novartis Pharmaceuticals (1) · POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company (1)
United States (19) · Canada (14) · United Kingdom (14) · Australia (11) · France (11) · Italy (10) · Japan (10) · South Korea (10) · Spain (10) · Brazil (9) · Poland (9) · Taiwan (9) · Belgium (8) · China (8) · Germany (8)
Abhishek Solanki, MD MS (1) · Alexandra Sokolova (1) · Ananya Choudhury, Professor (1) · Ashkan Mortezavi, MD, PhD (1) · Brian Chapin (1) · Jan Oldenburg, Professor (1) · Jessica Jensen (1) · Johan Lindberg, PhD (1)
PMID 18990168, PMID 22452894, PMID 22747660, PMID 26718929, PMID 26719232, PMID 28300506, PMID 28578639, PMID 29529169, PMID 30355464, PMID 30738780, PMID 31560068, PMID 31823152, PMID 32404868, PMID 32586393, PMID 32994091, PMID 33270906, PMID 33599706, PMID 34246347, PMID 34757812, PMID 34953525, PMID 35034502, PMID 35317973, PMID 35671327, PMID 36059000, PMID 36305957, PMID 36697317, PMID 36735603, PMID 36996380, PMID 37142371, PMID 37973477, PMID 39164518, PMID 39663356, PMID 39839782, PMID 40263079, PMID 40455815, PMID 40467357, PMID 40523369, PMID 40539499, PMID 40639383, PMID 41346252, PMID 41880608, PMID 42061373
2004 (1), 2016 (1), I01CX002277 (1), U10CA031946 (1), U10CA180888 (1)